Navigation Links
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
Date:7/2/2008

our and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA).

Abbott also supplies a private-label version of XIENCE V to Boston Scientific called the PROMUS(TM) Everolimus-Eluting Coronary Stent System. PROMUS is designed and manufactured by Abbott and supplied to Boston Scientific as part of a distribution agreement between the two companies.

Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its antiproliferative properties.

Additional information about XIENCE V, including important safety and effectiveness information, is available online at http://www.xiencev.com.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.

*Event rates are based
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
2. FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
3. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
4. Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications
5. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
6. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
7. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
8. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
9. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
10. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
11. Medicare Approves in Home Sleep Apnea Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... On September 11, Pharma IQ conducted an interview ... a session that he will lead on “Stem Cells” at ... 17-18, 2015 in London. In the interview posted ... to respond to several questions on the current state of ... cell toxicity, and future trends in the use of stem ...
(Date:9/29/2014)... CA (PRWEB) September 30, 2014 ... million burn injuries require medical attention. In the ... brings serious complications to battlefield medical care. More ... Iraq and Afghanistan. Burn wounds heal slowly, remain ... can be excessive, physically debilitating and functionally damaging. ...
(Date:9/29/2014)... TORONTO , Sept. 29, 2014 /PRNewswire/ - Portage Biotech ... Exchange: PBT.U), is pleased to announce that its three ... of Portage, who advanced $ 100,000 each in July ... have their Notes and related Coupons converted into 3,500,001 ... and carried 5% coupon. Both the Note and the ...
(Date:9/29/2014)... 29, 2014 Transparency Market Research, in ... SPPS, LPPS, HPPS, by Application - Cancer, Metabolic, CVS, ... and by Delivery) - Global Industry Analysis, Size, Share, ... the global peptide therapeutics market was worth US$14.1 billion ... by 2018 at an 8.7% CAGR. , The two ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4Faster Healing with Fewer Scars 2Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3
... Calif., Jan. 21 VNUS(R) Medical,Technologies, Inc. (Nasdaq: ... minimally invasive treatment of peripheral vascular disease,announced today that ... quarter ended December 31, 2007, after the close of ... regular quarterly teleconference at 2:00 p.m. PT,/ 5:00 p.m. ...
... Two Development Milestones in its Ofatumumab ... Collaboration With GlaxoSmithKline., COPENHAGEN, January 21 ... second and third development milestones,for ofatumumab (HuMax-CD20(R)) under the terms ... of the collaboration of DKK 87.2 million,was triggered by treatment ...
... company insiders knowingly misrepresented the ... ... Sobol Shapiro filed a,proposed class-action lawsuit on behalf of CellCyte ... the company and chief executive officer Gary A.,Reys, background, causing ...
Cached Biology Technology:VNUS Medical Technologies to Report Fourth-Quarter 2007 Results and Webcast Teleconference on February 7 2Genmab Reaches Milestones in Ofatumumab Collaboration 2Genmab Reaches Milestones in Ofatumumab Collaboration 3Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation 2Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation 3
(Date:9/30/2014)... 30, 2014  Spectra Automation, a trusted ... biotech and power generation industries, announced today ... Manager, an easy-to-use and cost-effective data collection, ... development laboratories. Most upstream ... analyzer systems. Accessing and consolidating data from ...
(Date:9/29/2014)... called Clostridium ramosum , coupled with a high-fat diet, ... this week in mBio , the online open-access journal ... team from the German Institute of Human Nutrition Potsdam-Rehbruecke in ... C. ramosum gained weight when fed a high-fat diet. ... less obese even when consuming a high-fat diet, and mice ...
(Date:9/29/2014)... story from 2009, "human activities in this area of the ... oil is increasingly grown for use as a cooking oil ... It has become the most widely produced edible oil in ... surpass that of soybean oil. , The environmental effects of ... to grow the crop, and the preferred method is fire. ...
Breaking Biology News(10 mins):Spectra Automation Introduces RECONN Bioprocess Manager 2Gut bacteria promote obesity in mice 2
... 2013 UT Southwestern Medical Center researchers report that ... to inflammatory disease, indicating that the production of a ... clock. The study published in the Nov. 8 ... pathway by which the body,s circadian clock controls the ...
... Science Foundation (NSF), in cooperation with interagency and ... awards under a program that supports multi- and ... and sustainability of the natural and living environment, ... the Arctic. Six projects have been ...
... URBANA, Ill. Despite a 12-year action plan calling for ... progress has been made, and there is no evidence that ... University of Illinois researchers have identified some of the biophysical ... "We are suggesting that a partnership of researchers work ...
Cached Biology News:UT Southwestern researchers identify how body clock affects inflammation 2UT Southwestern researchers identify how body clock affects inflammation 3NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 2NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 3NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 4NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 5NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 6Researchers suggest plan to address hypoxia in Gulf of Mexico 2Researchers suggest plan to address hypoxia in Gulf of Mexico 3